article thumbnail

Biosimilar Insulins Promise Patients New Choices, But Competition Is Still Lacking

MedCity News

The big three insulin manufacturers have cut prices across their product lineups, but potential competition from other biosimilar insulins is still in earlier stages of development. Insulin prices have long been a pain point for diabetics.

article thumbnail

Making Strategic Sense of Pharma’s New Race for Competitive Advantage

Fierce Pharma

The race for competitive advantage for pharma today is about far more than just innovative new molecules.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Patient Acquisition as a Competitive Advantage

Penrod

The patient intake experience is a patient’s first impression of your clinic, hospital, or practice. By approaching the intake experience as a competitive advantage, you will attract more patients, decrease patient leakage, and drive more revenue. Let’s seize this moment to redefine healthcare together.

article thumbnail

Study: Biosimilar Competition Did Not Consistently Lower Costs for Patients

Pharmacy Times

The results indicate the need for targeted policies so that biosimilar competition can increase cost savings and affordability for patients with commercial insurance.

article thumbnail

Eli Lilly Fatty Liver Drug Posts Promising Early Data, But Field Is Still Competitive

MedCity News

Eli Lilly reported 74% of patients treated with tirzepatide achieved resolution of metabolic dysfunction-associated steatohepatitis, or MASH. However, the Phase 2 results showed only “clinically meaningful” improvement in resolving liver fibrosis, a key measure of the drug’s potential competitiveness in a crowded field of contenders.

article thumbnail

Sustainable biosimilar competition in Europe: can it be achieved?

European Pharmaceutical Review

According to The Biosimilar Medicines Group, part of Medicines for Europe, a new report by IQVIA indicates there is a window of opportunity for the EU to foster future-proof biosimilar competition. Failure to attract biosimilar competition The report emphasised that there is a “huge” biosimilar void to 2032, the group shared.

article thumbnail

FTC order could ease biopharma competition

European Pharmaceutical Review

to address the potential competitive harm Amgen’s $27.8 Consolidation in the pharmaceutical industry has given companies the power and incentive to engage in exclusionary rebating practices, which can lead to sky-rocketing prices on essential medications,” stated Henry Liu, Director of the FTC’s Bureau of Competition.